AIFM2

Across TCGA pan-cancer cohorts, AIFM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AIFM2 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher AIFM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AIFM2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

COAD, PDAC, and LSCC are the cancer types where AIFM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	IV	0.565	1.000	.028	12	view →
PDAC	OS	Tertile	IV	0.414	0.973	.024	11	view →
LSCC	DFS	Median	III,IV	0.840	0.384	.008	9	view →
LUAD	OS	Quartile	III,IV	0.355	0.738	.039	2	view →
CCRCC	OS	Median	III,IV	0.921	0.663	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AIFM2–COAD (DFS)

Open the COAD breakdown →